• Tropifexor (LJN452): FXR Research Guide

  2026-09-04

  Tropifexor, also called LJN452, is a potent synthetic Farnesoid X Receptor agonist for mechanistic FXR signaling and intestinal epithelial barrier function research. Its reported EC50 is approximately 0.2 nM, but potency does not by itself establish tissue selectivity, therapeutic efficacy, or clinical utility.

• 3D Tumor Spheroids for Glioblastoma Stemness

  2026-09-03

  The reference study presents a streamlined 96-well 3D tumor spheroid assay for functionally assessing stem-like behavior in human glioblastoma and glioma cell lines. By reducing dependence on prolonged, multiround sphere-forming workflows, the method supports faster comparisons of experimental interventions while retaining the need for orthogonal stemness validation.

• Elobixibat hydrate: IBAT Inhibition for GI Research

  2026-09-03

  Elobixibat hydrate is a selective ileal bile acid transporter inhibitor that increases intestinal bile acid exposure and supports research on constipation, bowel preparation, and metabolic signaling. The C8720 product has low systemic exposure, high protein binding, and formulation-specific solvent guidance documented by the product information.

• Catalpol in Diabetes: Pharmacology, PK, and Safety

  2026-09-02

  This review integrates evidence that Catalpol, also indexed as Catalpinoside, may improve diabetes and protect against complications through coordinated effects on metabolism, inflammation, oxidative stress, and apoptosis. Its pharmacokinetic discussion, including evidence of blood–brain barrier passage and oral potential, helps define priorities for better-controlled preclinical and clinical studies.

• Smart Hydrogel Design for Diabetic Wound Healing

  2026-09-02

  The reference study introduces TGF-β1@MATH, an adhesive thermosensitive hydrogel that combines hollow mesoporous MnO2 nanozymes with controlled TGF-β1 delivery. Its integrated design addresses oxidative stress, tissue mechanics, and immune dysregulation, producing improved fibroblast activity, regulatory T-cell recruitment, and diabetic wound repair in mice.

• IPR-803: Translating uPAR Biology Into Strategy

  2026-09-01

  IPR-803 is a competitive urokinase receptor inhibitor designed to disrupt the uPAR–uPA interface that supports tumor invasion. This thought-leadership guide connects structural mechanism with assay design, formulation-aware translation, and strategic development in breast and pancreatic cancer models.

• Nonselective β-Blockers Delay HCT Hematopoietic Recovery

  2026-09-01

  The reference study identifies broad β-adrenergic blockade as a modifiable factor that can impair hematopoietic regeneration after allogeneic hematopoietic cell transplantation (HCT). Mouse experiments and retrospective human cohorts linked carvedilol-class exposure to delayed platelet engraftment and poorer survival, particularly when posttransplant chemotherapy was used for graft-versus-host disease prophylaxis.

• Machine Learning Discovery of New Senolytics

  2026-08-31

  The reference study shows that machine-learning models trained only on published senolytic data can prioritize active compounds despite small and heterogeneous datasets. Computational screening followed by human-cell validation identified ginkgetin, periplocin, and oleandrin, demonstrating a cost-efficient route for early senolytic discovery.

• N-Glycosylation, MerTK, and HCC Tumor Growth

  2026-08-31

  The reference study identifies N-glycosylation at MerTK Asn294 and Asn454 as a stabilizing mechanism that supports hepatocellular carcinoma growth, metabolic fitness, and stress survival. Its findings connect MerTK protein quality control with reactive oxygen species, oxidative phosphorylation, and tumor prognosis, while providing a rationale for testing glycosylation-directed interventions.

• USP11 and Female Susceptibility in Cushing’s Disease

  2026-08-30

  A 2025 study identifies the deubiquitinating enzyme USP11 as a sex-associated susceptibility factor in ACTH-secreting pituitary neuroendocrine tumors. Its data connect elevated USP11 in female tumors with TPIT stabilization, increased POMC transcription, and ACTH secretion, while also offering an initial basis for inhibitor discovery.

• 1-methyl Adenosine: Assay Workflows and Uses

  2026-08-29

  Build a defensible 1-methyl Ado workflow for intracellular profiling, cancer metabolism studies, and biomarker discovery. Stable isotope dilution, solid-phase cleanup, and chromatographic isomer separation convert a difficult nucleoside measurement into a practical assay strategy.

• AAL-993: VEGFR Inhibition for Angiogenesis Studies

  2026-08-28

  Explore how AAL-993, a selective VEGF receptor inhibitor, can sharpen tumor angiogenesis research by separating receptor-level blockade from downstream signaling effects. This article connects VEGFR pharmacology with assay lessons from a network pharmacology study of glioma biology.

• Mitochondrial Calcium Signaling in Ferroptosis

  2026-08-28

  The reference study identifies mitochondrial calcium uptake through MCU as a regulator of GPX4 acetylation and sustained anti-ferroptotic activity. Its genetic, biochemical, structural, and tumor-model data connect mitochondrial metabolism with ferroptosis control while also highlighting important limits for translating the mechanism into tissue-injury models.

• NSC 87877: A Causal Map of Shp2 Signaling

  2026-08-27

  NSC 87877 is a potent Shp2 inhibitor for separating catalytic phosphatase activity from broader SHP2 pathway effects. This article translates stroke-neuroinflammation findings into a rigorous assay strategy spanning EGF signaling, microglia, leukemia, and inflammatory pain research.

• Machine Learning Discovery of Senolytics

  2026-08-27

  Smer-Barreto et al. used cost-effective machine learning trained exclusively on published data to prioritize senolytic candidates despite sparse and heterogeneous evidence. Computational screening followed by human-cell validation identified ginkgetin, periplocin, and oleandrin, illustrating how data-driven prioritization can reduce early drug-discovery costs without replacing experimental confirmation.

7856 records 1/524 page Next 12345 下5页 Last page